
CISOVA®Ovarian Cancer Methylation Test (CDO1/HOXA9)
A single blood draw to detect early ovarian cancer
CDO1/HOXA9 dual-gene methylation test requiring only a single peripheral blood ctDNA draw — non-invasive auxiliary diagnosis, solving the challenge of early detection of the 'silent killer.'
Recommended companion kits
Use the DNA Isolation and Purifying Kit (Beijing Medical Device No. 20240021) for DNA extraction and purification, followed by DNA Methylation-Lightning MagPrep (Beijing Medical Device No. 20200110) for bisulfite conversion.
Robust clinical data support
Based on multi-center registered clinical trials, sensitivity and specificity both reach industry-leading levels.
Who needs this test?
- Benign/malignant differentiation for women with ovarian cysts or pelvic masses
- Early risk assessment for high-risk ovarian cancer populations
- Ovarian health screening for peri- and postmenopausal women
- Auxiliary diagnosis for suspected ovarian cancer patients
How is it applied clinically?
- Non-invasive early screening for ovarian cancer
- Benign/malignant stratification of pelvic masses to aid surgical decisions
- Follow-up monitoring for high-risk ovarian cancer populations
- Women's cancer screening programs at health checkup centers
Why choose us
China's first approved ovarian cancer methylation test product
Requires only a single blood draw with excellent patient compliance
ctDNA-based epigenetic testing — non-invasive and precise
Global patents and proprietary intellectual property
Frequently asked questions about this test
What is the CISOVA test?
CISOVA is a Class III in vitro diagnostic device (NMPA Reg. No. 20253402443) that detects CDO1/HOXA9 dual-gene methylation in plasma cell-free DNA — the first approved ovarian cancer methylation test in China.
How accurate is the CISOVA test?
Registration clinical trial data (1,421 samples) show 93.19% sensitivity for ovarian cancer and 92.78% specificity, supported by a real-world multi-center study of nearly 10,000 samples.
Can one tube of blood really detect ovarian cancer?
Yes. CISOVA captures methylation signals from circulating tumor DNA (ctDNA) in plasma, detecting ovarian cancer at the epigenetic level with >92% sensitivity and specificity in registration clinical trials. It is used for benign-vs-malignant differentiation of ovarian cysts and pelvic masses.
I found an ovarian cyst or pelvic mass on imaging. Should I get CISOVA?
Recommended. Imaging alone often cannot accurately distinguish benign from malignant masses. CISOVA detects tumor methylation signals from a blood sample, providing adjunctive stratification for surgical decision-making.
Who is suitable for the CISOVA test?
Women with ovarian cysts or pelvic masses needing benign-vs-malignant differentiation, individuals at high risk of ovarian cancer, perimenopausal and postmenopausal women for screening, and suspected ovarian cancer patients needing adjunctive diagnosis.
Request the IFU, clinical summary and pricing
Tell us your institution type and intended use. We reply within 1–2 business days with the documents below, and can arrange a technical call with our clinical team.
- IFU, registration certificate and sample requirements
- Clinical performance summary and published papers
- Distributor terms, kit configuration and logistics
The same methylation platform, two more cancers
CISPOLY covers cervical, endometrial and ovarian cancer with one non-invasive workflow.


